Select your injection site and clean the area with an alcohol swab in a circular motion, starting from the center and moving outward
Saxenda (liraglutide) Saxenda is a GLP-1 medication appropriate for adults who: Have obesity (BMI of 30 or above) Have overweight (BMI of 27 or above) along with a weight-related comorbid condition like high blood pressure, type 2 diabetes, or high cholesterol or triglycerides It is also approved for children ages 12 and above who weigh more than 132 pounds and are considered obese
Do not use it without a qualified prescriber if you have a personal or family history of medullary thyroid carcinoma or MEN 2
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and GIP/GLP-1 dual agonists (tirzepatide) carry the clinical evidence: STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024)
Performance Sleep, Performance Dose 20 units (1mg Tesamorelin / 200mcg Ipamorelin) Frequency 5 days / week Administration Subcutaneous Timing PM, 60-90 minutes after last meal, close to bedtime Vial Size 12mg (10mg Tesamorelin / 2mg Ipamorelin) Reconstitution 2mL Bacteriostatic Water Cycle Length 3 months on, 2 months off Vials / Month 2 Vials / Cycle 6 Do not combine with other GH-stimulating peptides such as CJC-1295/Ipamorelin
You might also experience blurred vision, nausea, or cold, clammy skin
.jpg)
